Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	387,526	289,599	707,754	967,489
Depreciation	347	259	694	695
Research and development (including stock-based compensation (Note 8))	114,454	114,192	237,779	283,913
Total operating expenses	502,327	404,050	946,227	1,252,097
Loss from operations	(502,327)	(404,050)	(946,227)	(1,252,097)
Other expense:
Interest expense	142,738	97,304	260,340	189,800
Total other expense	142,738	97,304	260,340	189,800
Net loss	(645,065)	(501,354)	(1,206,567)	(1,441,897)
Net loss attributable to the noncontrolling interest	768	523	1,273	3,692
Net loss applicable to Bion's common stockholders	$ (644,297)	$ (500,831)	$ (1,205,294)	$ (1,438,205)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.06)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	28,804,007	26,382,778	28,135,409	26,021,254